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ABSTRACT 
 
 Neonatal seizures often lead to the later development of epilepsy and other 
cognitive disabilities, which may in part be due to calcium (Ca2+)-permeable AMPA 
receptor (CP-AMPAR)-mediated increases in synaptic plasticity and neuronal 
excitability. AMPAR subunit trafficking and the mTORC1 pathway are thought to be 
regulated by CP-AMPAR activity, and both have been implicated in the epileptogenic 
changes that follow neonatal seizures. The most common cause of neonatal seizures is 
hypoxic-ischemic encephalopathy. Using an established rat model of neonatal hypoxia-
induced seizures, we demonstrate efficacy of the novel AMPAR-antagonist, perampanel, 
in suppressing seizures. We also attempt to demonstrate the efficacy of perampanel in 
reversing seizure-induced post-translational changes to GluR1 and two downstream 
targets of mTORC1, p70S6 kinase and ribosomal protein S6. However, due to limited 
time and insufficient sample numbers (n) we were unable to show any significant effect 
of perampanel on these protein targets. We could not replicate the seizure-induced 
increases in GluR1 subunit (Ser831/845), p70S6 kinase, and S6 phosphorylation that 
have previously been shown. We were also unable to replicate the efficacy of a different 
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AMPAR antagonist, NBQX, in reversing these seizure-induced increases. These two 
facts, when taken together with the low n, suggest that our lack of results are likely do to 
insufficient sample number, and do not necessarily indicate a lack of efficacy for 
perampanel. Considering perampanel’s favorable anticonvulsant effect in our model, and 
the previously demonstrated success of other AMPARs as antiepileptogenics, we are 
hopeful that a further and more in depth study of perampanel will yield more favorable 
results.  
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INTRODUCTION 
 
 The brain is one of the most complex and least understood organs in the body, yet 
we can simplify its function by considering it as a balance between excitation and 
inhibition. Neurons, the basic unit of the brain, can be either excitatory or inhibitory, and 
the delicate balance between these two types of neurons allows us to control our 
responses to the different stimuli we encounter every day. Any disruption to this normal 
balance can lead to problems. Seizures are one such disruption. Seizures come in many 
forms and have many different causes, but regardless of their etiology they are essentially 
an excess of excitation relative to inhibition in a particular area of the brain. Although 
single seizures are fairly common, occurring in about 7-10% of all people (Bear, 
Connors, & Paradiso, 2006), and have limited consequences, repeated seizures can be 
debilitating and their recurrence is termed epilepsy. Epilepsy is the second most common 
neurological disorder, affecting approximately 1% of all people in the United States, and 
it can be caused by a number of different things, including tumors, vascular disease, head 
trauma, genetic disorders, and various other insults (Bear et al., 2006). In addition, 
epilepsy is often comorbid with other neurological and psychological deficits, such as 
stroke, autism, and learning disabilities, making treatment difficult (Deonna & Roulet, 
2006; Hauser, Annegers, & Kurland, 1993; LaFrance, Kanner, & Hermann, 2008; Talos 
et al., 2012).  
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Neonatal Seizures 
Studies have shown seizures to be most prevalent during the neonatal period 
(Volpe, 2001), the first month of life, with an estimated incidence of 1.5-3.8/1000 live 
births in the United States and Canada (Ronen, Buckley, Penney, & Streiner, 2007; 
Silverstein & Jensen, 2007). One of the major causes of neonatal seizures is hypoxic-
ischemic encephalopathy (HIE) (Jensen, Applegate, Holtzman, Belin, & Burchfiel, 1991; 
Lombroso & Burchfiel, 1987; Volpe, 2001), which occurs when the brain is deprived of 
oxygen for an extended period of time. This can occur during birth as a result of perinatal 
asphyxia or respiratory arrest, or immediately after birth due a number of different 
problems, such as cardiopulmonary bypass to correct congenital heart defects (Jensen et 
al., 1991).  
Neonatal seizures increase the risk for the later development of epilepsy and other 
neurocognitive defects (Ronen et al., 2007), including autism, but neonatal seizures are 
notoriously difficult to diagnose and treat. Unlike the mature brain, the newborn brain is 
still undergoing extensive development, both anatomically and physiologically, and as a 
consequence seizures are shorter, less organized, and often lacking the more obvious 
clinical manifestations that accompany seizures in adults (Volpe, 2001). The behavioral 
correlates to neonatal seizures are subtle, and often resemble normal infantile movements 
(Silverstein & Jensen, 2007). Further complicating matters, electrographic seizures 
commonly have no clear clinical symptoms, a phenomenon known as “electroclinical 
dissociation”, thus requiring the use of electroencephalographic (EEG) monitoring for 
positive identification (Glykys et al., 2009; Sankar & Painter, 2005; Scher, Alvin, Gaus, 
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Minnigh, & Painter, 2003). Once diagnosed, doctors face the challenge of treating the 
seizures. Most antiepileptic drugs (AEDs) used in adults have never been tested 
specifically for use in neonates, and neonatal seizures are often refractory to many of 
these therapies (Frances E Jensen, 2009; Sankar & Painter, 2005; Silverstein & Jensen, 
2007). Additionally, there is concern that extended treatment with AEDs in children may 
have adverse effects on the many maturational processes occurring in the brain during 
this time (Russell M. Sanchez & Jensen, 2001). Indeed, studies have shown that neonates 
treated with phenobarbital, a commonly used AED for neonatal seizures, developed long-
term cognitive deficits (Farwell et al., 1990; Sulzbacher, Farwell, Temkin, Lu, & Hirtz, 
1999). In light of these challenges, recent research has focused on better understanding 
the unique mechanisms underlying neonatal seizures in an effort to develop more 
targeted, age-specific therapies.  
 
Animal Seizure Models 
 Rodent models have been used most commonly to study neonatal seizures. 
Seizures models can be created through the use of chemoconvulsants, such as kainate, 
flurothyl, and pilocarpine, surgically-induced stroke, electrical stimulation, or fluid 
percussion injury to replicate traumatic brain injury (Rakhade & Jensen, 2009). Although 
these models can be very useful for studying epilepsy in the adult brain, they are often 
accompanied by extensive neuronal cell death (Rakhade & Jensen, 2009), which is far 
less common following neonatal seizures. Rodent models of neonatal hypoxia-induced 
seizures (HS) more closely approximate the human disease state, featuring increased 
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post-HS neuronal excitability, cognitive deficits, and increased susceptibility to 
subsequent chemoconvulsant-induced seizures, in the absence of neuronal cell death 
(Jensen et al., 1991; Mikati et al., 2005; Rakhade et al., 2008, 2011; Sanchez et al., 2001). 
The end of the second week of life in rats (postnatal day 10-12) correlates to the neonatal 
period (32-40 gestational weeks) in humans, during which time the brain is undergoing a 
number of developmental changes that increase seizure susceptibility, and consequently 
this window is often used to study neonatal seizures (Rakhade & Jensen, 2009; Romijn, 
Hofman, & Gramsbergen, 1991; Talos, Fishman, et al., 2006). 
 
Factors Influencing Increased Seizure Susceptibility in Neonates 
 The neonatal period is a critical period for brain development. Earlier 
developmental processes lead to an overabundance of synaptic connections, and it is 
during the neonatal period that these connections are refined. This ability to eliminate 
non-functional synapses in favor of stronger connections is termed synaptic plasticity. 
Functional neuronal connections are positively selected for by increasing postsynaptic 
receptor density, thus increasing sensitivity to presynaptic signaling, and by increasing 
presynaptic neurotransmitter (NT) release. This process, called long-term potentiation 
(LTP), is activity-dependent and requires glutamate, the major excitatory 
neurotransmitter, and its receptors (Russell M. Sanchez & Jensen, 2001; Silverstein & 
Jensen, 2007). As a consequence of this, glutamate receptors are expressed at higher than 
adult levels during this period (Insel, Miller, & Gelhard, 1990; McDonald, Trescher, & 
Johnston, 1992). The different types of glutamate receptors include the ionotropic N-
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methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
(AMPA), and kainate receptors, and other metabotropic receptors. Adding to this state of 
hyperexcitability, expression of the classical inhibitory γ-amino-butyric acid (GABA) 
receptors is low during this time. All of this contributes to a critical period of increased 
neuronal excitability, which despite its necessity, also lowers the threshold for seizure 
induction, increasing the likelihood that an insult during this period could give rise to 
seizures (Figure 1) (Rakhade & Jensen, 2009).  
 
 
Figure 1: Maturational changes in glutamate and GABA receptor expression. The 
neonatal period in humans, equivalent to the first two postnatal weeks in rodents, is a 
period of heightened excitability as a result of developmental expression changes in 
excitatory glutamate receptors and inhibitory GABA receptors. AMPA and NMDA 
receptor expression peaks during the second postnatal week before declining to their 
adult levels. This increased expression is concurrent with very low GABA receptor 
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expression, which peaks much later in life. The combination of these events contributes 
to an enhanced neuronal excitability, which is necessary for activity-dependent 
synaptogenesis and synaptic plasticity. This period of time is crucial for normal brain 
development, but also provides a window of increased seizure susceptibility, as the 
hyperexcitable network has a lower threshold for seizure induction. Abbreviations: 
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, GABA = γ-amino-
butyric acid, NMDA = N-methyl-D-aspartate,  P (on x axis of rodent timeline) = 
postnatal day. (Figure amended from Rakhade et al., 2009). 
 
AMPA receptors (AMPARs) and NMDA receptors (NMDARs) are typically 
colocalized in the mature brain. NMDARs are calcium (Ca2+)-permeable, and elicit a 
slow, long lasting excitation in response to simultaneous glutamate binding and 
membrane depolarization. The Ca2+ influx triggers the activation of a number of kinases 
that increase both AMPAR ion conductance and AMPAR trafficking to the post-synaptic 
membrane (Breedlove, Rosenzweig, & Watson, 2007). This NMDAR-mediated 
regulation of neuronal excitability is the basic mechanism behind LTP, and is necessary 
for normal leaning and memory (Russell M. Sanchez & Jensen, 2001).  
NMDARs are heteromeric, composed of at least one NR1 subunit and additional 
NR2 or NR3 subunits, which are developmentally regulated. NR2B is the most common 
NR2 subunit during the neonatal period, and is expressed at higher levels than NR2A to 
the adult. The developmental switch from a preponderance of NR2B-containing 
NMDARs to NR2A-containing receptors, shortens the duration of glutamate-mediated 
excitatory currents. Longer NMDA-current durations in the immature brain increase 
synaptic plasticity and excitability (Sanchez & Jensen, 2001; Silverstein & Jensen, 2007). 
Rodent studies have shown that other NMDA subunits, namely NR2C, NR2D, and 
NR3A, are also elevated during the first two postnatal weeks (PNW), which decrease 
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sensitivity to magnesium blockage, further increasing excitability (Hollmann & 
Heinemann, 1994; Silverstein & Jensen, 2007; Wong et al., 2002). 
 AMPARs are involved in fast excitatory signaling, and unlike NMDARs are 
predominantly Ca2+-impermeable in the adult brain (Silverstein & Jensen, 2007). Four 
different AMPAR subunits, GluR1-4, assemble in different combinations to form a 
heterotetramer. The GluR2 subunit is particularly important, as it regulates Ca2+ 
permeability. Unlike the mature form, most AMPARs are Ca2+-permeable in the 
immature rodent and human brain due to the absence of the GluR2 subunit (Kumar et al.,  
2002). GluR2 levels stay very low until about the third PNW in rodents, after the 
neonatal period in humans (Talos et al., 2006; Talos et al., 2006a). These Ca2+-permeable 
AMPARs (CP-AMPARs) are similar in function to NMDARs, in that they can mediate 
marked increases in neuronal excitability (Sanchez & Jensen, 2001). The increased 
expression and subunit composition of both NMDARs and AMPARs during the neonatal 
period confer enhanced neuronal network excitability, and help explain the increased 
seizure incidence seen during this time window (Silverstein & Jensen, 2007). 
 
Seizure-induced Epileptogenic Changes 
 One of the most prominent and immediate consequences of seizures in the adult 
brain is neuronal cell death, and yet rodent models have shown a reduced incidence and 
severity of seizure-induced neuronal cell death in the immature brain (Haas et al., 2001; 
Sperber, 1996; Wasterlain et al., 2002). Originally, this lack of injury was thought to be 
indicative of a resistance to the pathological effects of seizures, but studies later showed 
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that rather than causing cell death, neonatal seizures instead trigger changes in receptor 
expression and neuronal connectivity (Brooks-Kayal, 2005; Sanchez et al., 2001; Swann 
& Hablitz, 2000). These changes produce long-term negative consequences unrelated to 
neuron loss, promoting epileptogenesis and an increased susceptibility to later-life 
seizures (Jensen et al., 1998; Jensen et al., 1992). Many of these changes involve an 
exacerbation of existing age-specific receptor expression patterns, delaying the normal 
developmental changes necessary for maturation. 
 Seizure-induced increases in Ca2+ influx through NMDARs and CP-AMPARs 
trigger activation of a number of kinases, including Ca2+/calmodulin-dependent protein 
kinase II (CaMKII), protein kinase A (PKA), and protein kinase C (PKC) (Rakhade et al., 
2008). CaMKII and PKA phosphorylate GluR1 at serine (Ser)831 and Ser845, 
respectively. Ser831 phosphorylation increases AMPAR channel conductance, while 
Ser845 phosphorylation regulates AMPAR open probability (increasing the probability 
that glutamate binding results in channel opening) and increases trafficking of GluR1-
containing AMPARs to the synapse. PKC phosphorylates GluR2 at Ser880, which causes 
GluR2 subunit internalization and therefore may increase the number of GluR2-lacking 
CP-AMPARs (Rakhade et al., 2008; Shepherd & Huganir, 2007). Additionally, in a rat 
model of HS, GluR2 mRNA expression showed a progressive decline over the first 48 hr 
following HS, which was followed by a significant decrease in GluR2 protein at 96 hr 
post-HS. Further experiments confirmed that this decrease was correlated with an 
increase in the number of CP-AMPARs (Sanchez et al., 2001). The combination of these 
seizure-induced modifications to the GluR1 and GluR2 subunits enhances AMPAR 
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signaling, particularly CP-AMPAR signaling, which in turn results in increased 
excitability and synaptic potentiation (Rakhade et al., 2008). 
Another important pathway activated by CP-AMPARs and NMDARs is the 
mammalian target of rapamycin complex 1 (mTORC1) pathway. The mTORC1 pathway 
plays an important role in regulating protein synthesis, and its dysfunction has been 
implicated in the genetic disorder tuberous sclerosis, which is commonly associated with 
seizures. Once activated, mTORC1, a protein kinase, phosphorylates (and activates) 
p70S6 kinase (p70S6K) and its downstream target, S6 ribosomal protein, which in turn 
increases protein synthesis, including synthesis of important synaptic plasticity proteins 
such as CaMKII and GluR1 (Figure 2) (Hoeffer & Klann, 2010; Talos et al., 2012).  
The long-term changes in neuronal excitability that result from synaptic plasticity 
require increased protein synthesis, and thus it would follow that an increase in mTORC1 
pathway activity might be a necessary consequence of seizure-induced increases in 
synaptic excitability (Hoeffer & Klann, 2010). Indeed, a recent study showed elevated 
mTORC1 pathway activity following HS, as evidenced by increased phosphorylation of 
the downstream effectors p70S6K and S6 protein levels (Talos et al., 2012). This 
increased mTORC1 activity provides a potential mechanism for the permanent seizure-
induced changes in neuronal connectivity. In essence, the hyperexcitable neuronal 
circuits involved in seizure generation are strengthened and maintained rather than 
gradually weaned, increasing susceptibility to further seizures later in life.  
10	  
 
Figure 2. Seizure-induced activation of the mTORC1 pathway. Neonatal seizures 
increase glutamate release secondary to increases in synaptic activity. Activation of CP-
AMPARs and NMDARs triggers an influx of Ca2+, which is turn initiates a signaling 
cascade that activates mTORC1. mTORC1 activates p70S6K and its downstream target, 
S6, a ribosomal protein that enhances translation. Over time, increased protein synthesis 
of synaptic plasticity proteins (such as CaMKII, and GluR1) can lead to long-term 
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heightening of neuronal excitability that increase susceptibility to later seizures and the 
subsequent development of epilepsy. (Figure amended from Talos et al., 2012). 
 
 
AMPAR Antagonists as AEDs 
 The AEDs currently in clinical use act only to suppress seizures, but do nothing to 
modify the long-term consequences of those seizures (Rakhade & Jensen, 2009). Because 
of their role in seizure susceptibility and link to seizure-induced epileptogenic changes, 
NMDARs and AMPARs have been presented as potential age-specific therapeutic targets 
for the prevention of later-life seizures. The use of NMDAR antagonists is complicated 
by the central role NMDARs play in brain development, as well as learning and memory 
throughout life (Silverstein & Jensen, 2007). Studies confirmed the importance of 
NMDARs in early brain development, as rats treated with the NMDAR antagonist, 
(+)MK801, during the first two PNWs showed extensive neuronal cell death 
(Ikonomidou et al., 1999). AMPAR antagonists, however, are not associated with this 
same cell death, and unlike NMDAR antagonists, they have been shown to be effective in 
preventing the acute and chronic effects of HS in neonatal rats (Aujla, Fetell, & Jensen, 
2009; Glier et al., 2004; Ikonomidou et al., 1999; Jensen et al., 1995). In a rat model of 
neonatal HS, the AMPAR antagonists 2,3-dihydroxy-6-nitro-7-sulfonyl-
benzo[f]quinoxaline (NBQX),  topiramate, and talampanel (GYKI-53773) effectively 
suppressed seizures when administered prior to induction of HS. Pretreatment with 
NBQX or topiramate also protected against increased susceptibility to second-hit seizures 
in adulthood and seizure-induced neuronal cell death, while talampanel protected only 
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against cell death (Aujla et al., 2009; Jensen et al., 1995; Koh & Jensen, 2001). Although 
these experiments were useful as a proof of principle, they had little clinical relevance, as 
antiepileptic therapies are always administered after and not prior to the initial seizure. 
Further study confirmed that NBQX and topiramate were indeed also effective in 
protecting against second-hit kainate (KA) induced seizures when administered 
immediately following initial HS (Koh et al., 2004).  
More recently, investigators have begun to focus their attention on a specific 
subset of AMPARs: CP-AMPARs, as these are developmentally upregulated in the 
immature brain. These CP-AMPARs are of particular interest because of the crucial role 
Ca2+ signaling plays in synaptic plasticity and other signaling cascases that have been 
implicated in epileptogenesis, such as seizure-induced post-translational changes in 
AMPARs and components of the mTORC1 pathway. To test the hypothesis that CP-
AMPARs play a role in seizure-induced increases in AMPAR phosphorylation, AMPAR 
antagonists were administered post-HS to see if they could prevent these changes. 
NBQX, topiramate, and talampanel protected against seizure-induced increases in 
CaMKII, PKA, and PKC activity, along with subsequent increases in the phosphorylation 
of GluR1 Ser831 and Ser845, which prevented AMPAR current potentiation (Rakhade et 
al., 2008). To confirm that these effects were in fact due to CP-AMPARs rather than 
NMDAR-dependent Ca2+ influx secondary to normal AMPAR activation, we developed a 
cell culture model of neurons that express CP-AMPARs. After isolating AMPAR 
activation (by pharmacological blockade of NMDAR signaling), we were able to show 
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CP-dependent phosphorylation of GluR1 Ser 831 and Ser 845 (unpublished data), the 
first study to show that CP-AMPARs are upstream of these seizure-induced changes.  
 In a different study, treatment with rapamycin, an mTOR inhibitor, attenuated 
HS-induced increases in p70S6K and S6 phosphorylation, and also protected against 
AMPAR potentiation and increased KA seizure susceptibility (Talos et al., 2012). Our 
recent work has looked at determining whether CP-AMPAR antagonists can indirectly 
prevent these seizure-induced increases in mTORC1 activity, and indeed preliminary data 
shows a reversal of HS-induced p70S6K phosphorlyation after treatment with NBQX 
(unpublished data). 
 
Perampanel 
 Perampanel (Fycompa), a selective noncompetitive AMPA antagonist, is an AED 
that was recently approved by the FDA in late 2012 for the adjunctive treatment of 
refractory seizures in epilepsy patients age 12 years and older. Three Phase III clinical 
trials demonstrated that perampanel resulted in a marked decrease in seizure frequency 
when administered concomitantly with patients’ current AEDs, in patients with 
uncontrolled seizures (French et al., 2012, 2013; Krauss et al., 2012). 
 Preclinical rodent studies showed that perampanel protects against a broad 
spectrum of seizure types, and has a much lower fifty percent effective dose (ED50) than 
many traditional AEDs, such as carbamazepine, and sodium valproate. Perampanel’s 
efficacy was tested in a number of different rodent seizure models, including audiogenic 
seizures, maximal electric shock-induced seizures, pentylenetetrazol seizures, 
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electroshock-induced seizures, and a kindling seizure model (Hanada et al., 2011). 
However, as is typical in initial preclinical and clinical studies for novel AEDs, both 
studies focused solely on drug efficacy in adults. As we have seen, AED efficacy in the 
immature brain requires a separate study because of the age-dependent mechanistic 
differences underlying seizure initiation and further propagation. Additionally, because 
both studies were conducted in adults, seizure reduction was used as the only outcome 
measure for drug efficacy, without consideration for the long-term epileptogenic effects 
that can result from neonatal seizures.  
 
The Present Study 
 In the clinic, seizure intervention strategies currently focus on seizure suppression 
as the primary outcome measure, with little attention paid to the long-term consequences 
of these seizures. These consequences are of particular significance in neonates, as 
neonatal seizures often lead to permanent changes that predispose patients to the 
development of epilepsy, and only recently has there been a push to better understand and 
prevent these changes. Through a number of recent studies, we have proposed that 
seizure-induced phosphorylation of GluR1 (Ser831 and Ser845), p70S6K, and S6 serve 
as potential biomarkers for epileptogenesis, and that these changes are downstream from 
CP-AMPARs. We have shown that AMPARs, and particularly CP-AMPARs, represent a 
promising age-specific therapeutic target, not only for seizure suppression, but also for 
prevention of the seizure-induced changes that often increase susceptibility to later-life 
seizures. Other AMPAR antagonists, including NBQX, topiramate, and talampanel, have 
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already been tested to this effect. The present study aims to build upon this evidence by 
testing the efficacy of perampanel, a novel AMPAR antagonist, in protecting against 
these changes. 
 Because perampanel is such a new AED, the literature on its usage is limited. 
Currently, the only animal studies performed using perampanel are preclinical studies 
performed by Eisai Co., the pharmaceutical company that discovered the drug. As these 
studies were conducted in older animals, using different seizure models, it was important 
that we first demonstrate the anticonvulsant efficacy of perampanel in our neonatal rat 
HS model before investigating its effect on our proposed epileptogenic biomarkers. To 
assess this, we compared the percent reduction in seizure frequency and total duration, 
relative to untreated controls, in rats pretreated with one of a series of different 
perampanel doses. These tests served the additional purpose of determining the optimal 
anticonvulsant dosage for use in our post-seizure treatment experiments.  
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SPECIFIC AIMS 
  
In order to document the anticonvulsant and antiepileptogenic efficacy of perampanel in 
an established neonatal rat model of hypoxic encephalopathy, we plan to: 
 (1) Evaluate the effect of perampanel pretreatment on seizure frequency and 
cumulative seizure duration. 	   (2) Determine the optimal anticonvulsant dosage for perampanel in our neonatal 
HS model. 
 (3) Evaluate the post-seizure treatment effect of perampanel on seizure-induced 
alterations in the phosphorylation of GluR1 (Ser831 and Ser845), p70S6K, and S6. 
 
 We expect these studies will show: 
 (1) Administration of perampanel prior to seizure induction results in a dose-
dependent decrease in both seizure frequency and cumulative seizure duration. 	   (2) Post-HS administration of perampanel, at the optimal anticonvulsant dosage, 
protects against seizure-induced increases in phosphorylation of GluR1 (Ser831 and 
Ser845), p70S6K, and S6. 
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METHODS 
 
Animals 
Male Long Evans rat pups (Charles River Laboratories, MA) were maintained in a 
temperature-controlled animal care facility with a 12 hr light-dark cycle. All procedures 
were in accordance with the guidelines of the National Institutes of Health’s Guide for the 
Care and Use of Laboratory Animals. The protocol was approved by the Animal Care 
and Use Committee at Children's Hospital Boston (protocol number: 11-05-1952R). We 
made all efforts to minimize animal suffering and the number of animals used. 
 
Hypoxia-induced Seizures 
 Postnatal day (P)10 rat pups were exposed to nonlethal graded global hypoxia for 
15 min in an airtight chamber into which nitrogen gas was rapidly infused, as previously 
described (Jensen et al., 1991; Rakhade et al., 2011). Briefly, oxygen concentration was 
maintained at 7% for 8 min, 5% for 6 min, and 4% for 1 min before termination of 
hypoxia. Littermate controls were separated from their dams and kept at room air for the 
duration of the experiment. Body temperature was maintained between 32-34° C on a 
circulating water heating pad, and all rats were returned to their dams within two hr.  
Seizures during hypoxia were videotaped and reviewed by an investigator blind to 
treatment, and scored for the number and cumulative duration of tonic-clonic seizures 
during the 15 min hypoxic episode. Seizures were characterized by head bobbing, wet 
dog shakes, and tonic-clonic head and limb movements, and previous studies have used 
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EEG monitoring to demonstrate that these behavioral automatisms are correlated with 
ictal electrographic changes (Cleary et al., 2013; Rakhade et al., 2011).  
 
Drug Preparation 
 Perampanel (Eisai Co., Tokyo, Japan) was dissolved in a 50% polyethylene glycol 
(PEG 300, Sigma-Aldrich), 40% H2O, 10% DMSO solution, and NBQX (Sigma-Aldrich) 
was dissolved in H2O. 
 
Pre-seizure Treatment 
 Four different doses of perampanel (0.1, 0.5, 1, 1.5 mg/kg) were tested for 
efficacy in suppressing hypoxia-induced seizures. Seizure suppression data was also used 
to determine the optimal antiepileptic dosage. Perampanel was administered via 
intraperitoneal (i.p.) injection 30 min prior to hypoxia. The 30 min pretreatment time was 
selected so that the peak perampanel plasma concentration coincided with the hypoxic 
period (Hanada et al., 2011). Rats were scored for seizure number and cumulative 
duration (as previously described), and behavior during the 30 min prior to hypoxia was 
reviewed in order to assess the sedative effect of each dose. Vehicle-treated rats with < 5 
seizures were excluded from further analysis. 
 
Post-seizure Treatment 
 Perampanel (0.5 or 1 mg/kg), NBQX (20 mg/kg), or vehicle was administered via 
i.p. injection immediately following hypoxia. Rats sacrificed at 24 hr post-hypoxia 
19	  
received an additional injection 12 hr after the initial injection. Rats with < 5 seizures 
were excluded form further analysis. Three treatment groups and one vehicle group were 
tested: low dose (0.5 mg/kg) perampanel (LDP), high dose (1 mg/kg) perampanel (HDP) 
alone, and NBQX alone. NBQX was used as a positive control, as we have previously 
demonstrated its efficacy in protecting against seizure-induced epileptogenic changes 
(Rakhade et al., 2008). Vehicle-treated rats received vehicle (50% PEG 300, 40% H2O, 
10% DMSO solution) i.p. injections of the same volume as they would have received if 
they were in one of the treatment groups.  
 
Western Blot Analysis 
 Hippocampal tissue from rats sacrificed at 1, 3, 12, and 24 hr following HS was 
dissected over cold PBS and both whole cell and membrane protein fractions were 
obtained, as previously described (Rakhade et al., 2008; Talos et al., 2012). Naïve 
littermate rats that had not been exposed to hypoxia were used as controls. Briefly, tissue 
samples were homogenized over ice in a sucrose buffer containing 250 µl HALT 
Protease and Phosphatase Inhibitor Cocktail and 100 µl phenylmethanesulfonyl fluoride 
per 10 ml of buffer. Whole cell and membrane fractions were collected from the same 
samples through a series of consecutive spins. Samples were first centrifuged for 10 min 
at 4,100 relative centrifugal force (rcf) at 4˚C, and supernatant was collected. This 
supernatant contained the whole cell fraction. One third of the supernatant was set aside 
for use as the whole cell fraction, while the remaining supernatant was processed further 
to obtain the membrane fraction. This supernatant was centrifuged for 10 min at 3,000 rcf 
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at 4˚C. The resulting supernatant was collected and centrifuged again for 10 min at 
13,000 rcf at 4˚C. Supernatant was discarded and the pellet was then resuspended in lysis 
buffer to obtain the membrane fraction. Total protein amounts were measured using the 
Bradford protein assay (Bio-Rad, CA), and samples were diluted for equal amounts of 
protein in each sample. Samples were run on 7.5% gradient Tris-HCl gels (Bio-Rad) and 
transferred onto polyvinylidene difluoride membranes via a semi-wet system (Invitrogen 
iBlot, Life Technologies Corp, NY). Membranes were blocked for 2 hr in 5% non-fat dry 
milk in Tris-buffered saline with 0.1% Tween 20 (Boston Bioproducts) before overnight 
incubation in primary antibody (GluR1 at 1:1000, Millipore; GluR1 phospho-Ser831 at 
1:1000, Millipore; GluR1 phospho-Ser845 at 1:1000, Millipore; S6 Ribosomal Protein at 
1:500, Cell Signaling; phospho-S6 (Ser 235/236) at 1:500, Cell Signaling; p70 S6 Kinase 
at 1:250, Cell Signaling; phospho-p70 S6 Kinase (Thr389) at 1:300, Cell Signaling; β-
actin at 1:10000, Invitrogen). Blots were then incubated for 1 hr in horseradish-
peroxidase conjugated secondary antibodies (0.1 g/ml anti-rabbit IgG, 0.5 g/ml anti-
mouse IgG, Invitrogen). Protein bands were visualized by chemiluminescence using the 
Image Reader LAS 3000 digital system and Image Gauge 4.0 software (Fuji Film Life 
Sciences, Japan). To control for loading differences across each lane, the optical densities 
(OD) for each protein were normalized to β-actin. These normalized values were then 
expressed as a percent or ratio of average control expression, and averaged for each time 
point and/or treatment group. Phospho-protein/total protein ratios were calculated 
similarly. 
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Statistical Analysis 
 Group measures are expressed as mean ± standard error of the mean (SEM); error 
bars also indicate SEM. Statistical analysis for differences between group means was 
performed using a two-tailed t-test for post-seizure time course experiments, and one-way 
analysis of variance (ANOVA) with a post hoc Bonferroni procedure for multiple group 
comparisons (GraphPad Prism, La Jolla, CA).  
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RESULTS 
 
Perampanel suppresses hypoxia-induced seizures 
 Graded global hypoxia induced acute seizures in 69% of vehicle-treated rats (9 of 
13 rats ≥ 5 seizures). Seizures were characterized by head bobbing, wet dog shakes, and 
tonic-clonic head and limb movements. During the 15 min hypoxic episode vehicle-
treated rats (n = 9) averaged 9.2 ± 0.7 seizures, with an average cumulative seizure 
duration of 249 ± 38.1 s (Figure 2A, B).  
To determine treatment efficacy, seizure frequency and cumulative seizure 
duration were compared between treatment groups. Consistent with previous studies, 
treatment with NBQX (n = 11) effectively suppressed hypoxia-induced seizures (Jensen 
et al., 1995). Compared to vehicle-treated rats, NBQX reduced seizure frequency and 
cumulative duration by 94% and 97%, respectively (0.6 ± 0.5, 7.1 ± 5.9 s, p < 0.001), and 
completely suppressed seizures in 82% of rats. The lowest perampanel dose tested (0.1 
mg/kg) had only a modest effect on seizure activity (n = 6, 6.3 ± 1.8, not significant (ns); 
125 ± 42.2 s, p < 0.05), with 31% and 50% decreases in frequency and duration, 
respectively. In contrast, 0.5 mg/kg perampanel reduced seizure frequency by 71% and 
cumulative duration by 83% (n = 11, 2.6 ± 0.6, 42.4 ± 10.9 s, p < 0.001), while 1 mg/kg 
perampanel resulted in even greater reductions of 79% and 86% (n = 11, 1.9 ± 1.2, 35.1 ± 
23.6 s, p < 0.001), compared to vehicle. Interestingly, although both the 0.5 and 1 mg/kg 
perampanel caused similar reductions in seizure activity, the 1 mg/kg dose completely 
suppressed seizures in 73% of rats, compared with only 27% for the 0.5 mg/kg dose. 
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Figure 3. Perampanel attenuates seizure frequency and cumulative duration. The 
number of hypoxia-induced seizures (A) and cumulative seizure duration (B) were 
plotted for each treatment group. Vehicle treated rats (n = 9) had an average of 9.2 ± 0.7 
seizures, with an average cumulative seizure duration of 249 ± 38.1 s. Compared to 
vehicle-treated rats, treatment with NBQX reduced seizure frequency by 94% and 
cumulative duration by 97% (n = 11, 0.6 ± 0.5, 7.1 ± 5.9 s). Although the lowest dose of 
perampanel (0.1 mg/kg) had little efficacy (n = 6, 6.3 ± 1.8, 125 ± 42.2 s), administration 
of 0.5 mg/kg perampanel decreased seizure frequency and duration by 71% and 86% (n = 
11, 2.6 ± 0.6, 42.4 ± 10.9 s), respectively. The higher 1 mg/kg dose showed even greater 
efficacy, reducing seizure frequency by 79% and cumulative duration by 86% (n = 11, 
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1.9 ± 1.2, 35.1 ± 23.6 s), compared to vehicle. Mean ± SEM. Error bars indicate SEM. 
Statistical differences are relative to vehicle. * p < 0.05, *** p < 0.001. 
 
Seizure-induced changes in GluR1 
 The effect of hypoxic seizures on GluR1 Ser831 and Ser845 phosphorylation was 
assessed by western blotting in hippocampal tissue collected at 1, 3, 12, and 24 hr post-
HS. Due to technical problems, the β-actin primary antibody did not work on the 1 hr and 
12 hr blots used for this experiment. As a result of this, protein expression at these time 
points could not be normalized to actin, and was therefore excluded from further analysis. 
HS caused a slight increase in total GluR1 at 3 hr (n = 3, 173 ± 35.9% control, ns), which 
remained elevated at 24 hr (n = 3, 135 ± 3.1% control, p < 0.05), relative to control levels 
(Fig 4A). That same period saw a slight increase in phosphorylation of GluR1 Ser831 at 3 
hr (n = 3, 147 ± 48.4% control, ns) before a return to baseline at 24 hr (n = 3, 109 ± 
28.1% control, ns, Fig 4B). GluR1 Ser845 phosphorylation also appeared to increase 
slightly at 3 hr (n = 3, 133 ± 26.5% control, ns) and remained elevated at 24 hr (n = 3, 
123 ± 18.5% control, ns, Fig 4C). However, further analysis of the ratio of 
phosphorylated Ser831 and Ser845 to total GluR1 revealed no significant changes (Fig 
4D, E). 
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Figure 4. Seizure-induced alterations in GluR1 expression and phosphorylation. 
Western Blot analysis was performed on hippocampal tissue obtained at 3, and 24 hr 
post-HS, in order to assess seizure-induced changes in GluR1 expression and 
phosphorylation at Ser831 and Ser845. ODs for total GluR1, phospho-GluR1 Ser831 (P-
Ser831), and phospho-GluR1 Ser845 (P-Ser845) were normalized to actin, then 
normalized to the average control, and averaged for each time point. Expression of (A) 
total GluR1, (B) P-Ser831, and (C) P-Ser845 were plotted as a percent of controls. 
Additionally, the ratio of (D) P-Ser831 to total GluR1 and (E) P-Ser845 to total GluR1 
were plotted. HS = hypoxia-induced seizures. Mean ± SEM. Error bars indicate SEM. 
Statistical differences are relative to control. * p < 0.05.  
 
Seizure-induced changes in mTORC1 pathway activity 
 The effect of hypoxic seizures on S6 and p70S6K phosphorylation was assessed 
by western blotting in hippocampal tissue collected at 1, 3, 12, and 24 hr post-HS. HS 
caused a transient increase in the mTORC1 downstream target, phospho-S6 (n = 3, 150 ± 
22.1% control, ns), at 1 hr, however, no changes were seen in phospho-p70S6K at that 
time (n = 3, 103 ± 71% control, ns). There were no significant changes in total S6 or 
p70S6K expression during the first 12 hr post-HS, although there did appear to be an 
increase in both S6 (n =3, 272 ± 64.9% control, ns) and p70S6K (n = 3, 177 ± 93.3% 
control, ns) at 24 hr. Further analysis of the ratio of phospho-S6 to total S6 showed an 
increase at 1 hr (n = 3, 1.68 ± 0.53, ns), consistent with the increase seen in phospho-S6. 
No significant changes were seen in the ratio of phospho-p70S6K to total p70S6K. 
 
 
 
 
27	    
28	  
Figure 5. Seizure-induced alterations in the expression and phosphorylation of S6 
and p70S6K. Western Blot analysis was performed on hippocampal tissue obtained at 1, 
3, 12, and 24 hr post-HS, in order to assess seizure-induced changes in S6 and p70S6K 
phosphorylation. ODs for total S6, phospho-S6 (P-S6), total p70S6K, and phospho-
p70S6K (P-p70S6K) were normalized to actin, then normalized to the average control, 
and averaged for each time point. Expression of (A) P-S6, (B) total S6, (D) P-p70S6K, 
and (E) total p70S6K were plotted as a percent of controls. Additionally, the ratio of (C) 
P-S6 to total S6 and (F) P-p70S6K to total p70S6K were plotted. HS = hypoxia-induced 
seizures. Mean ± SEM. Error bars indicate SEM. 
 
Post-seizure treatment effect of perampanel on GluR1 phosphorylation 
 Neither treatment with NBQX, LDP, nor HDP of the perampanel doses had any 
effect on HS-induced increases in total GluR1 at 3 hr, however LDP caused a significant 
decrease in total GluR1 at 24 hr (n = 3, 61.2 ± 3.0% control, p < 0.05) compared to 
vehicle-treated rats (n = 3, 135 ± 3.1% control). There also appeared to be a slight 
decrease in GluR1 Ser831 phosphorylation at 24 hr following treatment with NBQX (n = 
3, 60.0 ± 17.4% control, ns) and HDP (n = 3, 55.0 ± 10.6% control, ns), compared to 
vehicle (n = 3, 108.6 ± 28.1% control), however, it is important to note that this decrease 
did not represent a return to baseline, as Ser831 phosphorylation was not initially 
increased by HS. GluR1 Ser845 phosphorylation was also reduced at 24 hr following 
treatment with both LDP (n = 3, 74.9 ± 5.1% control, ns) and HDP (n = 3, 78.9 ± 3.5% 
control, ns), compared to vehicle (n = 3, 123 ± 18.5% control). No significant changes in 
Ser831 or Ser845 phosphorylation were seen at 3 hr.  
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Figure 6. Post-seizure treatment effect of NBQX, 0.5 and 1 mg/kg perampanel on 
GluR1 subunit phosphorylation. Rat pups were treated immediately following HS with 
NBQX, LDP, HDP, or vehicle. Western Blot analysis was performed on hippocampal 
tissue obtained at 3, and 24 hr post-HS, in order to assess the efficacy of these drugs in 
reversing seizure-induced changes in GluR1 expression and phosphorylation at Ser831 
and Ser845. ODs for total GluR1, phospho-GluR1 Ser831 (P-Ser831), and phospho-
GluR1 Ser845 (P-Ser845) were normalized to actin, then normalized to the average 
control, and averaged for each time point. Expression of total GluR1 at (A) 3 hr and (D) 
24 hr, P-Ser831 at (B) 3 hr and (E) 24 hr, and P-Ser845 at (C) 3 hr and (F) 24 hr was 
plotted as a percent of controls. HS = hypoxia-induced seizures, LDP = low dose (0.5 
mg/kg) perampanel, HDP = high dose (1 mg/kg) perampanel. Mean ± SEM. Error bars 
indicate SEM. Statistical differences are relative to HS + vehicle. * p < 0.05.  
 
Post-seizure treatment effect of perampanel on mTORC1 pathway activity 
 NBQX, LDP, and HDP were administered post-HS to determine whether they 
could effectively reduce the seizure-induced increases in S6 phosphorylation seen at 1 hr 
(n = 3, 150 ± 22.1% control, ns). Although NBQX had no effect, LDP decreased 
phospho-S6 (n = 2, 84.5 ± 14.4% control, ns) to levels near baseline. HDP appeared to 
also have some effect (n = 3, 124 ± 54.0% control, ns), although to a lesser degree. Total 
S6 levels remained unchanged, except for an apparent increase in rats treated with LDP 
(n = 2, 180 ± 25.6% control). A closer look at the ratio of phospho-S6 to total S6 revealed 
a decrease after treatment with either LDP (n = 2, 0.49 ± 0.15, ns) or HDP (n = 3, 1.08 ± 
0.38, ns), compared to vehicle-treated rats (n = 3, 1.68 ± 0.27), although it should be 
noted that the decreased ratio seen after treatment with LDP is likely primarily due to the 
large increase in total S6 seen at that time. 
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Figure 7. Post-seizure treatment effect of NBQX, 0.5 and 1 mg/kg perampanel on S6 
phosphorylation at 1 hr. Rat pups were treated immediately following HS with NBQX, 
LDP, HDP, or vehicle. Western Blot analysis was performed on hippocampal tissue 
obtained at 1 hr post-HS, in order to assess the efficacy of these drugs in reversing 
seizure-induced changes in S6 at this time. ODs for total S6, and phospho-S6 (P-S6) were 
normalized to actin, then normalized to the average control, and averaged for each 
treatment group. Expression of (A) P-S6 and (B) total S6 were plotted as a percent of 
controls. Additionally, the ratio of (C) P-S6 to total S6 was plotted. HS = hypoxia-
induced seizures, LDP = low dose (0.5 mg/kg) perampanel, HDP = high dose (1 mg/kg) 
perampanel. Mean ± SEM. Error bars indicate SEM. 
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DISCUSSION 
 
 The present study provides preclinical support for the use of the AMPAR 
antagonist, perampanel, in the treatment of neonatal seizures. In a clinically relevant 
model of hypoxia-induced neonatal seizures, administration of perampanel prior to the 
induction of global hypoxia elicited significant decreases in both seizure frequency and 
cumulative seizure duration. The post-seizure efficacy of perampanel in reversing 
seizure-induced alterations in the phosphorylation of GluR1 (Ser831 and Ser845), 
p70S6K, and S6 is less clear, as we were unable to replicate these previously reported 
changes. So although the anticonvulsant activity of perampanel in this model is 
promising, further study will be required in order to reliably establish its antiepileptic 
efficacy. 
 
Neonatal Seizure Treatment 
 The standard therapy for neonatal seizures is treatment with phenobarbital or 
phenytoin, yet studies have shown only limited efficacy in reducing seizure frequency 
(Jensen, 2009; Sankar & Painter, 2005). Left untreated, neonatal seizures are associated 
with an increased incidence of later-life epilepsy and other cognitive defects (Ronen et 
al., 2007). Recent studies have implicated increased phosphorylation of GluR1, p70S6K, 
and S6 as potential biomarkers for epileptogenesis in neonates, and have demonstrated 
that these changes are downstream of seizure-induced increases in CP-AMPAR 
activation (Rakhade et al., 2008; Talos et al., 2012). As such, CP-AMPARs represent a 
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potential age-specific therapeutic target for preventing the seizure-induced changes that 
increase susceptibility to later-life seizures.  
 The AMPAR antagonist, perampanel, was recently FDA approved for clinical use 
as an adjunctive treatment for refractory seizures. While the use of the AMPAR 
antagonists NBQX, topiramate, and talampanel have been shown effective in preventing 
HS-induced increases in GluR1 phosphorylation, their effect on mTORC1 pathway 
activity has yet to be investigated (Rakhade et al., 2008). Perampanel provides an 
opportunity to further validate our proposed epileptogenic biomarkers, and directly 
analyze the connection between CP-AMPARs and mTORC1 activation. 
 
Efficacy of Perampanel in Suppressing Seizures 
 Although AMPAR antagonists have proven effective in a number of epilepsy 
models, none have been specifically tested for clinical use in infants. NBQX and 
topiramate are not well suited for clinical trials in neonates, as NBQX has additional non-
specific effects, and neither drug is available for parenteral administration, which is 
necessary in critically ill neonates. Talampanel is available in a parenteral formulation, 
but is not FDA approved. Perampanel, however, can be administered parenterally and 
was recently FDA approved, and as such is uniquely positioned for translation into 
clinical trials for use in neonates.  
In line with prior reports, the present study demonstrated that NBQX effectively 
suppressed seizures in our neonatal HS model (F. E. Jensen et al., 1995). Using a range of 
doses consistent with those shown to be effective in adults, perampanel suppressed 
34	  
seizures in a dose dependent manner within the range of 0.1-1 mg/kg, with a maximal 
effect at 1 mg/kg (Hanada et al., 2011). While the lowest 0.1 mg/kg dose of perampanel 
showed only modest efficacy, increasing the dose to 0.5 and 1 mg/kg resulted in 
progressively greater attenuation of seizure activity, with the 1 mg/kg dose completely 
suppressing seizures in 73% of treated rats. A higher dose of 1.5 mg/kg was also tested, 
but this dose had a large sedative effect on the rats, a common side effect of high doses of 
AMPAR antagonists, that made it impossible to determine whether lack of seizure 
activity was due to the anticonvulsant effect or was merely secondary to sedation.  
This is the first study to test the anticonvulsant activity of perampanel in a 
neonatal seizure model. Future studies will need to address the safety of the drug in 
neonates, evaluate whether perampanel alters susceptibility to second-hit seizures. We 
previously demonstrated that there was no increase in constitutive neuronal cell death 
following administration of talampanel to normal P10 rats, and that treatment with 
talampanel prior to HS protected against enhanced neuronal injury following later-life 
KA-induced seizures (Aujla et al., 2009). NBQX and topiramate were equally effective in 
protecting against KA seizure susceptibility, and it is likely that perampanel will have 
similar protective effects (Koh et al., 2004).  
 
Post-seizure Treatment Effect for Perampanel 
 Seizure-induced increases in CaMKII, PKA, and mTORC1 activity are thought to 
contribute to long-term changes in neuronal connectivity and receptor expression that 
result in epileptogenesis and increased seizure susceptibility in later life (Hoeffer & 
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Klann, 2010; Rakhade et al., 2008; Talos et al., 2012). The phosphorylation status of the 
downstream targets of these kinases (GluR1 (Ser831/845), p70S6K, and S6) have 
therefore been proposed as surrogate biomarkers for these epileptogenic changes, and 
used as a novel outcome measure for determining the long-term treatment efficacy of 
different drugs (Rakhade et al., 2008; Talos et al., 2012). Here we attempted to replicate 
the seizure-induced increases in the phosphorylation of GluR1 (Ser831/845), p70S6K, 
and S6 and demonstrate the efficacy of perampanel in reversing these post-translational 
changes. However, perhaps in part due to limited time and large sample numbers (n) 
required to obtain significant statistical power, we were unable to show any significant 
effect of perampanel on these protein targets.  
In contrast to previous reports, seizures caused a significant increase in total 
GluR1 at 24 hr post-HS, which was reversed by treatment with LDP (Rakhade et al., 
2008). This increase could potentially be explained by an enhancement of mTORC1 
pathway activity, which activates the synthesis of certain proteins, including GluR1 
(Hoeffer & Klann, 2010; Talos et al., 2012). This pathway also increases CaMKII 
synthesis, which should in turn result in elevated phosphorylation of GluR1 at Ser831 
(Talos et al., 2012). However, as we were unable to replicate the significant increases in 
phosphorylation of GluR1 Ser831 (and Ser845) previously reported over the first 24 hr 
post-HS, the significance of the increased GluR1 expression is unclear (Rakhade et al., 
2008). We did see a slight increase in phospho-GluR1 Ser 831 at 3 hr and a slight 
increase in phospho-GluR1 Ser845 at 3 hr and 24 hr, but none of these changes were 
significant. 
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Considering the potential connection between increased GluR1 expression and 
mTORC1 activity, and taking into account previous reports, we expected to see elevated 
phosphorylation of the protein kinase p70S6K and its target S6 post-HS (Talos et al., 
2012). Indeed, phospho-S6 appeared to be transiently (although insignificantly) increased 
at 1 hr post-HS, however, we saw no changes in phospho-p70S6K at this time. Since S6 
is phosphorylated by activated p70S6K, we would expect to see an increase in phospho-
p70S6K either prior to or concomitant with an increase in phospho-S6. Talos et al, found 
that there was a time lag between p70S6K and S6 phosphorylation, but it is highly 
unlikely that p70S6K phosphorylation increased and then returned to baseline levels all 
within the first hour (Talos et al., 2012). The Talos et al study also reported elevated 
phosphorylation of p70S6K and S6 at 12 hr and 24 hr, respectively, much later than the 1 
hr increase we report here. Taken together, these facts suggest that the small increase in 
phospho-S6 at 1 hr is not in fact real.  
In the absence of any significant HS-induced changes in GluR1 (Ser831/845), 
p70S6K, and S6 phosphorylation, the post-seizure efficacy of perampanel is difficult to 
assess. There were no significant reductions in GluR1, p70S6K, and S6 phosphorylation 
following treatment with either LDP or HDP, however, this does not necessarily indicate 
a lack of efficacy for perampanel. We intended to use NBQX, which has previously been 
shown effective in reversing seizure-induced increases in GluR1 phosphorylation, as a 
means of comparing perampanel’s efficacy to prior data (Rakhade et al., 2008). The fact 
that we were unable to replicate neither those prior results, nor the post-HS increase in 
37	  
phosphorylation, taken together with the low n, suggest that our lack of results are most 
likely do to insufficient sample number.  
 
Conclusions 
We show that perampanel, at doses similar to those tested in adult rats, effectively 
attenuates seizure activity in a rat model of neonatal hypoxia-induced seizures. Although 
our data on the post-seizure efficacy of perampanel proved inconclusive, we believe this 
is due to a low sample number and is not necessarily reflect negatively on perampanel. 
Considering perampanel’s favorable anticonvulsant effect in our model, and the 
previously demonstrated success of other AMPARs as antiepileptogenics, we believe that 
perampanel has potential both as an acute treatment for seizure suppression and as a long-
term therapy aimed at protecting against increased seizure susceptibility in later-life. 
Perampanel is still a very novel drug, and we are hopeful that further and more in depth 
studies will yield more favorable results. 
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